Panax notoginseng for Health & Longevity - Quick Reference Sheet

Panax notoginseng for Health & Longevity

Created on 07/30/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 4.8 Audit

A traditional ginseng-family root with a two-way effect on blood, slowing bleeding while improving flow. Its most consistent action is reducing blood-cell stickiness and supporting circulation, with add-on signals after stroke and heart attack. Evidence is weak and mostly from ill patients; generally well-tolerated, but blood-thinner effects are unpredictable and it should be avoided in pregnancy. (Full Review)

Protocol

Oral Dose
1–3 g/day
Whole-root powder; standardized extracts dosed to label. Start low (~0.5–1 g) and increase over 1–2 weeks.
Timing
With food, morning/midday
Split the daily amount into two doses for steadier exposure.
Form
Raw, steamed, or extract
Raw powder stops bleeding; steamed is more tonifying; extracts standardized to saponin content.
Time to effect
Circulatory Benefits
Weeks
Symptomatic cardiovascular effects build over weeks of consistent use.
Hemostatic Effect
Relatively fast
Bleeding-related action of the raw powder.

Benefits

Contraindications
  • Pregnancy or breastfeeding (all trimesters)
  • Active bleeding or recent hemorrhagic stroke
  • Bleeding disorders or low platelet count
  • Surgery or procedure within 7–14 days
  • Allergy to notoginseng or ginseng-family plants
Key Interactions
  • Anticoagulants (warfarin, dabigatran, rivaroxaban, apixaban)
  • Antiplatelet drugs (aspirin, clopidogrel, ticagrelor)
  • NSAIDs (ibuprofen, naproxen)
  • Blood-thinning or blood-pressure supplements (ginkgo, garlic, fish oil, vitamin E, ginger)
  • Antidiabetic drugs (metformin, sulfonylureas, insulin)
  • CYP3A4-metabolized drugs (statins, calcium-channel blockers, immunosuppressants)

Risk & Side Effects

  • High: Common mild adverse effects
  • Medium: Hypersensitivity and allergic reactions; bleeding risk with blood thinners
  • Low: Overstimulation; preparation- and quality-related reactions
  • Speculative: Dencichine-related neurotoxicity; reproductive and pregnancy harm; hormone-like effects

Monitoring

Marker Target Why
Platelet count ~150–400 ×10⁹/L Baseline clotting capacity; screens for low platelets
INR ~0.8–1.1 (off anticoagulants) Detects excessive blood thinning
hs-CRP < 1.0 mg/L Tracks systemic inflammation
LDL cholesterol < 100 mg/dL Follows the lipid angle of cardiovascular benefit
Fasting glucose / HbA1c ~70–90 mg/dL / < 5.4% Monitors the metabolic effect and additive risk with diabetes drugs
eGFR > 90 mL/min/1.73m² Baseline and ongoing kidney function
ALT / AST ~10–30 U/L Liver function, since the saponins are liver-metabolized

Cadence: Baseline before starting, a follow-up at about 4–8 weeks, then every 6–12 months during continued use; recheck clotting tests whenever the dose changes or an interacting drug is added.

Qualitative Assessment

  • Energy and exercise tolerance
  • Frequency of chest tightness or exertional symptoms
  • Ease of bruising or any unusual bleeding
  • Cognitive clarity and mood
  • Sleep quality